51. Scleroderma Clinical trials / Disease details

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03558854 (ClinicalTrials.gov)	August 28, 2018	3/5/2018	Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients	Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Patients With Systemic Sclerosis	Systemic Sclerosis	Drug: Acetylsalicylic acid;Drug: Placebo oral capsule	Federal University of São Paulo	NULL	Completed	18 Years	65 Years	All	70	Phase 4	Brazil
2	EUCTR2009-013468-37-GB (EUCTR)	29/09/2010	17/03/2010	A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon. - Asasantin retard therapy in the management of Raynaud's phenomenon	A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon. - Asasantin retard therapy in the management of Raynaud's phenomenon	Primary Raynaud's Phenomenon and Systemic Sclerosis MedDRA version: 12.1;Level: LLT;Classification code 10042953;Term: Systemic Sclerosis MedDRA version: 12.0;Classification code 10037917;Term: Raynaud's phenomenon	Trade Name: Asasantin Retard ® Product Name: ASASANTIN Retard INN or Proposed INN: aspirin INN or Proposed INN: dipyridamole	Royal National Hospital for Rheumatic Disease	NULL	Not Recruiting			Female: yes Male: yes	70	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom